Astria Therapeutics (NASDAQ:ATXS) Stock Price Up 6.8% – Here’s What Happened

Astria Therapeutics, Inc. (NASDAQ:ATXS) rose 6.8% on Thursday . The stock traded as high as $12.18 and last traded at $12.04. Approximately 181,621 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 644,293 shares. The stock had previously closed at $11.27.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ATXS shares. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Friday, September 27th. Oppenheimer increased their price target on Astria Therapeutics from $25.00 to $26.00 and gave the company an “outperform” rating in a report on Tuesday, August 13th. TD Cowen started coverage on Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 price target for the company. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Astria Therapeutics presently has a consensus rating of “Buy” and an average target price of $25.20.

Astria Therapeutics Price Performance

The stock has a 50 day moving average price of $11.56 and a two-hundred day moving average price of $10.49. The firm has a market capitalization of $629.85 million, a price-to-earnings ratio of -4.94 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, research analysts expect that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astria Therapeutics

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares during the period. Tidal Investments LLC purchased a new position in Astria Therapeutics in the first quarter valued at $1,664,000. Sofinnova Investments Inc. purchased a new position in Astria Therapeutics in the second quarter valued at $552,000. ClariVest Asset Management LLC purchased a new position in Astria Therapeutics in the second quarter valued at $731,000. Finally, Ameritas Investment Partners Inc. boosted its holdings in Astria Therapeutics by 135.6% in the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock valued at $70,000 after purchasing an additional 2,861 shares during the period. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.